@ScottWaudbyHaemResLeics

The Ernest and Helen Scott Haematological Research Institute

[@ScottWaudbyHaemResLeics @HaemResLeic]

Research on blood cancer happens @uniofleicester

[Harriet Walter @HarrietSWalter]

Pleased to share some new PhD opportunities advertised within LCRC @uniofleicester to start this year including one within our institute https://t.co/3jQCYOkabX @HaemResLeic

[@ScottWaudbyHaemResLeics @HaemResLeic]

@SiFTW @ielyaas_cloete @LeukUK Congratulations @SiFTW @IelyaasCloete and team! It has been a real pleasure collaborating with you on this project

[ECMC Network (@ecmc-uk.bsky.social) @ECMC_UK]

Harriet Walter (Leicester ECMC) is a co-author on a Phase I/II study looking at EZH2/EZH1 inhibitor in solid tumours or hematologic malignancies & reporting preliminary Phase II results at #ASCO23. Check out abstract #3094, poster #292 at 8 AM – https://t.co/JB2KsgMzRL

[Harriet Walter @HarrietSWalter]

Great day for @HaemResLeic with @isogenicaltd and other university colleagues yesterday supported by @IPH_UK @uniofleicester @uolcollegecourt working on existing funding awards @UKRI_News @Impact_Aim_Mrc and building new collaborations.

[Research at Leicester's Hospitals @LeicResearch]

Congratulations to the @uniofleicester who have successfully renewed their bid to host an #NIHR-#CRUK Experimental Cancer Medicine Centre. The #ECMC works alongside our Hope Cancer Trials Centre @Leic_hospital to develop and deliver the latest cancer treatments for patients.

[@ScottWaudbyHaemResLeics @HaemResLeic]

@michieCLLlab @UofGlasgow @UofGCancerSci @POG_LRC Congratulations Alison!

[Hope Against Cancer @hopeagnstcancer]

Thank you Dr Matt Ahearne for taking the time to talk to us 💙

Hope Against Cancer works in partnership with local universities and hospitals to make sure that Leicestershire is a hub of expertise in cancer research and treatment.

https://t.co/T3TyIojToZ

[@ScottWaudbyHaemResLeics @HaemResLeic]

Looking for a PhD on blood cancer? Wonder how T cells fitness could predict response to immunotherapy? We have an exciting MRC AIM iCase PhD project using a multi-omics approach https://t.co/CwHVBIAgKk application deadline: 9th January 2022.

[@ScottWaudbyHaemResLeics @HaemResLeic]

We have an exciting opportunity for a MSc or PhD to join us as a Research Assistant to evaluate a novel therapeutic agent in blood cancer
https://t.co/cOxDqwVU23

[BSH - Haematology @BritSocHaem]

A new, chemotherapy-free treatment for chronic lymphocytic leukaemia (CLL) is to be available on the NHS, it has been announced. https://t.co/rgi8AXJ38k

[University of Leicester @uniofleicester]

📰 IN THE NEWS: Researchers from the Leicester Cancer Research Centre have helped develop a genetic test to predict a common type of leukaemia (via @leicslive).
Read more 👇
https://t.co/bbLTVhXDTk #CitizensofChange

[Hope Against Cancer @hopeagnstcancer]

Following the Hope Cancer Trials Centre's expansion, here is what Professor Anne Thomas, the clinical lead for the centre, has to say ⬇️

Thank you everyone who has supported us and contributed to our cause 💙

#charity #fundraising #donate #nonprofit #support

[@ScottWaudbyHaemResLeics @HaemResLeic]

Breaking News: we have an exciting translational iCase PhD project available @HaemResLeic @uniofleicester to work in collaboration with @isogenicaltd to develop and assess novel therapeutic antibodies for treatment of lymphoma. @ImpactMrc

https://t.co/mmGBHbbteh

[Graham Collins @graham74GC]

Do join @DrChrisPFox, @MJAhearne, Prof Tim Illidge & myself at what should be a fascinating symposium on T-cell lymphoma. New @BritSocHaem guidelines on PTCL soon, so v timely. 3 scintillating talks & hopefully a lively Q&A. So get the coffee on and join us 8am, 12th November!

[Blood Cancer UK @bloodcancer_uk]

And here it is 😁 👇

https://t.co/cpOiSXBOYR

[@ScottWaudbyHaemResLeics @HaemResLeic]

Vikki's paper is out in Haematologica's August issue. A massive piece of work looking at the dependency of different BCL-2 family proteins for survival in DLBCL and their potential use as therapeutic targets.

Congratulations to all authors! @viklarr @MartinJSDyer Meike Vogler

[Haematologica @Haematologica]

In #DLBCL, the heterogeneous response to #BH3-mimetics is mediated by selective interactions between BAX, BAK and anti-apoptotic #BCL-2 proteins.
https://t.co/ABKUBgvaZG

[@ScottWaudbyHaemResLeics @HaemResLeic]

Patients with blood cancer could be offered a tailored course of treatment in the future, after Leicester academics successfully trialled the use... https://t.co/QDjr5rfIki

[@ScottWaudbyHaemResLeics @HaemResLeic]

Coming from around UK, from around the World but all @HaemResLeic so proud to work @uniofleicester and to live in this vibrant city #TogetherInHope #WeAreLeicester

[Nishan Canagarajah @NCanagarajah]

Leicester is an incredible city. There is so much diversity and unity in one place. It’s more important now than ever to come together and shine a light on what is great about our city. Let us shape our future together. #TogetherInHope #WeAreLeicester

[@ScottWaudbyHaemResLeics @HaemResLeic]

This study confirms the promising efficacy of tirabrutinib both as monotherapy or in combination with other BCR signaling pathway inhibitors. 6 patients treated @Leic_hospital at the Hope Clinical Trial Facility @MartinJSDyer @HarrietSWalter @hopeagnstcancer

[@ScottWaudbyHaemResLeics @HaemResLeic]

Results of the Phase Ib Study using Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia are now published. https://t.co/mVaNSf5NZY